In 2024, Time Magazine recognized three distinguished scientists for their groundbreaking work in the field of weight loss drugs. Among them were Professor Daniel Joshua Drucker, Professor Joel Francis Habener, and Associate Professor Svetlana Mojsov. These researchers were honored for their collective efforts in developing effective drugs for treating diabetes and obesity.
Their work focused on insulin and incretins, specifically GLP-1, which plays a crucial role in controlling blood sugar levels and weight. Through their research, they identified a key link between insulin and incretins that has led to the development of innovative treatments for various diseases. Their findings have resulted in the creation of several drugs like Ozempic, Wegovy, Mounjaro, and Zepbound.
Associate Professor Svetlana Mojsov was also recognized by Time Magazine for her pioneering work in synthesizing GLP-1 and developing antibodies against it. Her contributions have been instrumental in advancing our understanding of GLP-1 and its impact on insulin levels. The use of GLP-1-based drugs has been approved in the US for treating diabetes and obesity with potential applications in reducing the risk of cardiovascular diseases. Ongoing research is exploring further uses of these drugs in combating Alzheimer’s disease, Parkinson’s disease, kidney diseases, and liver disease.
The recognition of Associate Professor Svetlana Mojsov by Time Magazine highlights the importance of her pioneering work in the field of weight loss drugs that was previously overlooked by major international biomedical awards. This acknowledgment aligns with the comprehensive evaluation criteria of the VinFuture Award, which underscores the groundbreaking contributions of these scientists.
In addition to their accolades from Time Magazine, these researchers have also received the VinFuture Awards for their revolutionary work on GLP-1 that has paved the way for significant advancements in the treatment of various diseases. Their dedication to scientific research and innovation continues to shape the future of healthcare as we know it today.